Corona Remedies IPO
Corona Remedies IPO
Corona Remedies Limited is an India-focused branded pharmaceutical company specializing in developing and marketing products across high-growth chronic therapeutic areas, primarily women’s healthcare, cardio-diabeto, pain management, and urology. The company is recognized as the second-fastest-growing among the top 30 firms in the Indian Pharmaceutical Market (IPM) by domestic sales. It operates two manufacturing facilities in Gujarat and Himachal Pradesh and leverages a pan-India marketing network of 2,671 medical representatives.
Investment Timeline
🤖 Smart Analysis
*AI score is algorithmic and for educational purposes only.
🎯 Application Strategy
Action: 👍 CONSIDER - Decent opportunity for diversification
Lots: Apply 1-2 lots based on risk appetite
⏳ Timing Advice
⚡ URGENT: Apply on DAY 1 MORNING - Extremely high demand! Allotment probability very low
Key Factor Analysis
Issue Details
Object of the Issue
The company proposes to utilize the Net Proceeds from the Issue towards the following objects:
- The IPO is entirely an Offer for Sale (OFS). The company will not receive any proceeds. All funds raised (₹655.37 Cr) will go to the selling shareholders (promoters and marquee investors).
Frequently Asked Questions
What is the current GMP of Corona Remedies IPO?
What is the AI Prediction for Corona Remedies IPO?
When will the allotment for Corona Remedies IPO be announced?
What is the listing date for Corona Remedies IPO?
Liability Disclaimer: Ipofly.com is an informational platform. We are not SEBI registered. The information provided here (including GMP and AI analysis) is for educational purposes only and should not be considered financial advice. Investments in the stock market are subject to market risks. Please consult your financial advisor before investing.